The estimated Net Worth of Eric J Hyllengren is at least $270 Тысяча dollars as of 16 August 2024. Eric Hyllengren owns over 1,070 units of Atara Biotherapeutics Inc stock worth over $205,722 and over the last 2 years he sold ATRA stock worth over $63,988. In addition, he makes $0 as Vice President и Investor Relations & Finance at Atara Biotherapeutics Inc.
Eric has made over 6 trades of the Atara Biotherapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,070 units of ATRA stock worth $7,094 on 16 August 2024.
The largest trade he's ever made was selling 28,648 units of Atara Biotherapeutics Inc stock on 16 May 2024 worth over $17,762. On average, Eric trades about 9,208 units every 65 days since 2023. As of 16 August 2024 he still owns at least 24,756 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Eric Hyllengren stock trades at the bottom of the page.
Eric Hyllengren is the Vice President, Investor Relations & Finance at Atara Biotherapeutics Inc.
Eric's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS, CA, 91320.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier и Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: